[go: up one dir, main page]

MX2017014880A - Composiciones farmaceuticas y uso de las mismas. - Google Patents

Composiciones farmaceuticas y uso de las mismas.

Info

Publication number
MX2017014880A
MX2017014880A MX2017014880A MX2017014880A MX2017014880A MX 2017014880 A MX2017014880 A MX 2017014880A MX 2017014880 A MX2017014880 A MX 2017014880A MX 2017014880 A MX2017014880 A MX 2017014880A MX 2017014880 A MX2017014880 A MX 2017014880A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
present
provides pharmaceutical
see formula
micronized compound
Prior art date
Application number
MX2017014880A
Other languages
English (en)
Other versions
MX380547B (es
Inventor
Liu Zhongzhou
Fu Chongdong
Shi Bin
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of MX2017014880A publication Critical patent/MX2017014880A/es
Publication of MX380547B publication Critical patent/MX380547B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención brinda composiciones farmacéuticas que comprenden el Compuesto A micronizado y su uso. (ver Fórmula).
MX2017014880A 2015-05-25 2016-05-24 Composición que comprende un inhibidor de fgfr1/kdr micronizado y el uso del mismo en el tratamiento de tumores neuroendocrinos. MX380547B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/079650 WO2016187767A1 (en) 2015-05-25 2015-05-25 Pharmaceutical compositions and use thereof
PCT/CN2016/083098 WO2016188399A1 (en) 2015-05-25 2016-05-24 Pharmaceutical compositions and use thereof

Publications (2)

Publication Number Publication Date
MX2017014880A true MX2017014880A (es) 2018-04-10
MX380547B MX380547B (es) 2025-03-12

Family

ID=57392304

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014880A MX380547B (es) 2015-05-25 2016-05-24 Composición que comprende un inhibidor de fgfr1/kdr micronizado y el uso del mismo en el tratamiento de tumores neuroendocrinos.

Country Status (26)

Country Link
US (1) US20180153890A1 (es)
EP (1) EP3302483B1 (es)
JP (1) JP6878309B2 (es)
KR (1) KR102573278B1 (es)
CN (1) CN107613984B (es)
AU (1) AU2016269304B2 (es)
BR (1) BR112017024126B8 (es)
CA (1) CA2985379C (es)
CY (1) CY1123408T1 (es)
DK (1) DK3302483T3 (es)
ES (1) ES2796575T3 (es)
HR (1) HRP20200935T1 (es)
HU (1) HUE050697T2 (es)
LT (1) LT3302483T (es)
MX (1) MX380547B (es)
MY (1) MY188169A (es)
PH (1) PH12017502148A1 (es)
PL (1) PL3302483T3 (es)
PT (1) PT3302483T (es)
RS (1) RS60355B1 (es)
RU (1) RU2712187C2 (es)
SG (1) SG10202106375UA (es)
SI (1) SI3302483T1 (es)
SM (1) SMT202000281T1 (es)
TW (1) TWI714588B (es)
WO (2) WO2016187767A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190276439A1 (en) * 2016-11-18 2019-09-12 Hutchison Medipharma Limited Method of treating solid tumors
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
CN114085214A (zh) * 2020-08-25 2022-02-25 和记黄埔医药（上海）有限公司 索凡替尼杂质及其制备方法和用途
US20220073642A1 (en) * 2020-09-07 2022-03-10 Hutchison Medipharma Limited Methods of using surufatinib in treating advanced pancreatic and extra-pancreatic neuroendocrine tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
AU2003230691A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
AU2005222632B2 (en) * 2004-03-15 2012-02-09 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AR078411A1 (es) * 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
CN102070618B (zh) * 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体
CN102775385A (zh) * 2011-05-10 2012-11-14 湖南有色凯铂生物药业有限公司 N-取代苯基-n’-取代杂环脲类化合物及其作为抗癌药物的应用

Also Published As

Publication number Publication date
HK1245113A1 (zh) 2018-08-24
KR102573278B1 (ko) 2023-09-01
KR20180006422A (ko) 2018-01-17
MY188169A (en) 2021-11-24
EP3302483A4 (en) 2019-02-27
RU2017139880A3 (es) 2019-10-03
NZ737544A (en) 2021-06-25
AU2016269304B2 (en) 2021-04-15
EP3302483A1 (en) 2018-04-11
EP3302483B1 (en) 2020-04-15
JP6878309B2 (ja) 2021-05-26
PL3302483T3 (pl) 2020-11-02
JP2018515587A (ja) 2018-06-14
MX380547B (es) 2025-03-12
BR112017024126B1 (pt) 2023-04-11
DK3302483T3 (da) 2020-06-15
AU2016269304A1 (en) 2017-11-30
LT3302483T (lt) 2020-06-25
SI3302483T1 (sl) 2020-07-31
US20180153890A1 (en) 2018-06-07
SMT202000281T1 (it) 2020-07-08
HUE050697T2 (hu) 2020-12-28
CY1123408T1 (el) 2021-12-31
PT3302483T (pt) 2020-06-16
CN107613984B (zh) 2021-04-30
TWI714588B (zh) 2021-01-01
BR112017024126A2 (pt) 2018-07-31
CA2985379C (en) 2023-08-01
BR112017024126B8 (pt) 2023-05-09
HRP20200935T1 (hr) 2020-09-18
RS60355B1 (sr) 2020-07-31
ES2796575T3 (es) 2020-11-27
WO2016188399A1 (en) 2016-12-01
WO2016187767A1 (en) 2016-12-01
SG10202106375UA (en) 2021-07-29
TW201641108A (zh) 2016-12-01
CN107613984A (zh) 2018-01-19
PH12017502148A1 (en) 2018-05-28
RU2017139880A (ru) 2019-06-25
RU2712187C2 (ru) 2020-01-24
CA2985379A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
CL2016000925A1 (es) Inhibidores de bromodominio
CL2016002772A1 (es) Composiciones de insulina de rápida acción
DK3529248T3 (da) Farmaceutiske sammensætninger
CR20160538A (es) Combinación
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
MX2017000619A (es) Composiciones plaguicidas.
MX376057B (es) Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion.
PL3405178T3 (pl) Preparaty/kompozycje zawierające inhibitor btk
BR112017016465A2 (pt) composto heterocíclico e composição farmacêutica que o compreende
CY1122287T1 (el) Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
UY37153A (es) Sulfonilamidas sustituidas para combatir parásitos animales
CO2017011295A2 (es) Piroglutamato de vortioxetina
BR112017002090A2 (pt) formulação de fator viii
CY1123408T1 (el) Φαρμακευτικες συνθεσεις και χρηση των αυτων
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
MX2017008373A (es) Compuestos, composiciones y metodos.
JOP20190159A1 (ar) توليفة من مثبط mcl-1 ومركب تاكسان، استخداماتها وتركيباتها الصيدلانية
DK3474902T3 (da) Farmaceutisk sammensætning der omfatter fluor-18-mærkede gasser
BR112016024236A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
EP3654955C0 (en) PHARMACEUTICAL COMPOSITIONS